This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Payton, M.
Right arrow Articles by Sim, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Payton, M.
Right arrow Articles by Sim, E.

 Previous Article  |  Next Article 

Journal of Bacteriology, February 1999, p. 1343-1347, Vol. 181, No. 4
0021-9193/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Cloning and Characterization of Arylamine N-Acetyltransferase Genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: Increased Expression Results in Isoniazid Resistance

Mark Payton,1 Roy Auty,1 Rupika Delgoda,1 Martin Everett,2 and Edith Sim1,*

Department of Pharmacology, University of Oxford, Oxford OX1 3QT,1 and Research and Development, Glaxo-Wellcome plc, Stevenage, Hertfordshire SG1 2NY,2 United Kingdom

Received 9 September 1998/Accepted 3 December 1998


    ABSTRACT
Top
Abstract
Text
References

Arylamine N-acetyltransferases (NATs) are found in many eukaryotic organisms, including humans, and have previously been identified in the prokaryote Salmonella typhimurium. NATs from many sources acetylate the antitubercular drug isoniazid and so inactivate it. nat genes were cloned from Mycobacterium smegmatis and Mycobacterium tuberculosis, and expressed in Escherichia coli and M. smegmatis. The induced M. smegmatis NAT catalyzes the acetylation of isoniazid. A monospecific antiserum raised against pure NAT from S. typhimurium recognizes NAT from M. smegmatis and cross-reacts with recombinant NAT from M. tuberculosis. Overexpression of mycobacterial nat genes in E. coli results in predominantly insoluble recombinant protein; however, with M. smegmatis as the host using the vector pACE-1, NAT proteins from M. tuberculosis and M. smegmatis are soluble. M. smegmatis transformants induced to express the M. tuberculosis nat gene in culture demonstrated a threefold higher resistance to isoniazid. We propose that NAT in mycobacteria could have a role in acetylating, and hence inactivating, isoniazid.


    TEXT
Top
Abstract
Text
References

Arylamine N-acetyltransferases (NATs) are cytosolic enzymes which acetylate arylamines and hydrazines by transfer of the acetyl group from acetyl coenzyme A to the free amino group forming an acetylamide (33). The same enzymes are also able to catalyze the transfer of an acetyl group to the oxygen of an arylhydroxylamine (10, 32). NAT is widespread among eukaryotes (28, 33), and the existence of NAT in prokaryotes was, until recently, thought to be confined to Salmonella typhimurium (32). S. typhimurium NAT has the ability to N-acetylate arylamines and the hydrazine isoniazid (24, 32). In humans there are now known to be two isoenzymes, NAT1 and NAT2 (2). The human enzyme NAT2, whose substrates include sulfonamide-based antibacterial compounds (20), was first identified as the enzyme which inactivates the front-line antitubercular drug isoniazid (9). The sulfonamides sulfamethoxazole and p-aminosalicylate are acetylated predominantly by the human isoenzyme NAT1 (4, 13), as is p-aminobenzoic acid (18, 30). Both NAT1 (22, 34) and NAT2 (for a review, see reference 5) show polymorphism in human populations. Identification of human NAT2 polymorphisms provides an explanation for the different effective therapeutic doses of isoniazid in fast and slow acetylators (8, 9).

We report here the cloning of the nat genes from the eubacteria Mycobacterium smegmatis and Mycobacterium tuberculosis and show that the M. smegmatis NAT is active with a range of substrates, including isoniazid. We demonstrate, using antibodies raised against recombinant S. typhimurium NAT, that NAT is present in wild-type M. smegmatis. It was reasoned that if isoniazid was acetylated by NAT prior to activation, an elevated resistance to isoniazid would be observed if more NAT were present in M. smegmatis. We therefore expressed the M. tuberculosis nat gene in M. smegmatis using the shuttle vector pACE-1 (21) and observed the effect of induction of NAT protein on the growth of mycobacteria cultured in isoniazid.

Identification of nat genes in M. smegmatis and M. tuberculosis. A radiolabelled DNA probe representing a 264-bp HindIII fragment of S. typhimurium nat (32), corresponding to a region which spans two highly conserved areas in NAT, was used to isolate clones containing nat from M. smegmatis and M. tuberculosis (strain H37Rv). Gridded libraries containing at least two copies of the M. smegmatis and M. tuberculosis genomes were screened, and double positives were selected. All sequence analyses were performed by an automated (ABI 377) sequencer (The Advanced Biotechnology Centre, ICSM, London) with Fidelase, an enzyme suitable for regions rich in GC. Amino acid sequences representing putative open reading frames of M. smegmatis and M. tuberculosis NAT are illustrated in Fig. 1 together with a PILEUP comparison of known NAT amino acid sequences. The sequence of M. tuberculosis NAT corresponds exactly to the sequence deposited previously in the database (3), assigned as a hypothetical protein. NAT from the genome of Escherichia coli is also shown for comparison and was obtained by database searching, again assigned as a hypothetical protein (1). These sequences are illustrated in order to emphasize the common features in all NAT proteins; the conserved PFENL and RGGDC sequences (where D is either W or Y), containing the active-site cysteine and the arginine residues proposed to participate in the reaction mechanism (6, 32), are indicated in Fig. 1. The M. smegmatis nat gene open reading frame is >60% identical to M. tuberculosis nat, and these genes have GC contents of 69 and 65%, respectively, compatible with the genes being of mycobacterial origin (15). The mycobacterial NATs each show amino acid sequence identities of ~35 and 30% with the NATs from S. typhimurium and human NAT2, respectively (Fig. 1).


View larger version (117K):
[in this window]
[in a new window]
  		FIG. 1.   Amino acid alignment of the predicted M. smegmatis and M. tuberculosis NAT against NAT homologues of eukaryotic and prokaryotic origins. Amino acids are represented by the single-letter code. Numbers refer to amino acid positions of the aligned sequences, which are ranked in order of decreasing similarity in comparison with human NAT1. Codes on the left identify the relevant NAT sequence. Human(1) is human NAT1, accession no. P18440; Human(2) is human NAT2, accession no. P11245; Hamster(1) is hamster NAT1, accession no. P50292; Mouse(1) is mouse NAT1, accession no. P50294; Hamster(2) is hamster NAT2, accession no. P50293; Mouse(2) is mouse NAT2, accession no. P50295; E. coli is E. coli NAT, accession no. P77567; S. typhimurium is S. typhimurium NAT, accession no. Q00267; M. tuberculosis is M. tuberculosis NAT, accession no. P96848, which codes for a hypothetical protein (3) and has the same sequence as the M. tuberculosis NAT described in this report; and M. smegmatis is M. smegmatis NAT, accession no. AJ006588. Amino acids showing identity in all NATs are shown in white on a black background, while residues showing conservation and similarity in more than four species of NAT are indicated in white on a grey background. A dot represents a gap introduced to maximize homology. The proposed active site cysteine is indicated (§) (32), as are the arginine residues thought to participate in the reaction (dagger ) (6, 32). Regions of complete identity are underscored.

Expression of mycobacterial nat genes in E. coli. The predicted open reading frames of S. typhimurium, M. smegmatis, and M. tuberculosis nat genes were cloned into the expression vector pET28b (Novagen). E. coli cells (DE23-pLysS) were transformed with the constructs for recombinant protein production, which also encode a 2.1-kDa thrombin-cleavable N-terminal histidine tag. Recombinant protein production was carried out as described previously (24). E. coli cells were disrupted by sonication on ice, eight times each for 30 s with 15-s intervals between sonications, and centrifuged at 100,000 × g for 60 min at 4°C. Supernatant was removed, and the pellet was resuspended in an equal volume of resuspension buffer (50 mM Tris-HCl [pH 8.0], 2 mM EDTA, 4 mM dithiothreitol, and 1 mM Pefabloc [protease inhibitor]). It was demonstrated that the nat sequence from M. smegmatis induces the synthesis of a protein of ~32 kDa, close to the predicted size of 32.3 kDa, corresponding to the open reading frame coding for the NAT protein (275 amino acids) plus the hexahistidine fusion tag (2.1 kDa). The recombinant NAT protein from M. smegmatis was found associated predominantly with the insoluble pellet (Fig. 2A, lane 4). The molecular mass of the M. tuberculosis NAT protein (275 amino acids) plus the hexahistidine tag is predicted to be 33.5 kDa. The NAT recombinant protein of M. tuberculosis has a molecular mass of around 32 kDa and is found exclusively in the insoluble pellet when produced in E. coli (Fig. 2A, lane 2). The molecular mass of the S. typhimurium NAT protein (283 amino acids) with the hexahistidine tag is predicted to be 34.3 kDa and is found predominantly in the soluble, supernatant fraction (Fig. 2A, lane 3).


View larger version (48K):
[in this window]
[in a new window]
  		FIG. 2.   Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of recombinant NAT proteins in E. coli. (A) Gels were stained with Coomassie blue. E. coli cells were transformed with pET28b alone (lanes 1) or with pET28b constructs containing the coding region of nat from M. tuberculosis (lanes 2), S. typhimurium (lanes 3), or M. smegmatis (lanes 4). Lysates were used to generate supernatants (S) and pellets resuspended in the original volume of lysate (P). Individual lanes were loaded with 15 µl of each fraction. The upper and lower arrows indicate the migration of recombinant S. typhimurium and mycobacterial NATs, respectively. Lane M, molecular mass markers. (B) Western blot analysis using an antiserum (1:100,000) against recombinant S. typhimurium NAT developed by using an enhanced chemiluminescence detection system (27). Lane 1, supernatant from E. coli transformed with pET28b alone; lane 2, pellet from E. coli transformed with M. tuberculosis NAT; lane 3, supernatant from E. coli transformed with S. typhimurium NAT; lane 4, supernatant from E. coli transformed with M. smegmatis NAT.

An antiserum raised against purified recombinant S. typhimurium NAT (24) was used to confirm the identity of the induced protein bands observed in Fig. 2A. The immunization schedule and detection were carried out as previously described (27). The antiserum was used at a dilution of 1:100,000 and did not cross-react with the control E. coli supernatant that had been transformed with vector alone under the conditions used (Fig. 2B, lane 1). The antiserum does identify a low level of endogenous E. coli NAT when used at a dilution of 1:50,000 (data not shown). The antiserum, at 1:100,000, cross-reacted with a strong band in the supernatant of E. coli transformed with nat from S. typhimurium (Fig. 2B, lane 3) and in the supernatant of E. coli which had been transformed with the putative nat from M. smegmatis (Fig. 2B, lane 4). No band corresponding to M. tuberculosis NAT was found in the supernatant fraction (data not shown). However, a protein in the pellet fraction of E. coli cells expressing the M. tuberculosis nat gene was shown to cross-react with the antiserum to S. typhimurium NAT. The degree of recognition of the NAT from M. tuberculosis in the pellet (Fig. 2B, lane 2) is less than that expected based on the protein staining intensity (Fig. 2A, lane 2P), suggesting that the antiserum to the S. typhimurium NAT cross-reacts less with the M. tuberculosis protein than with the M. smegmatis protein (Fig. 2A, lane 4S, and Fig. 2B, lane 4).

The detection of NAT activity using the arylamines anisidine, 4-aminoveratrole, and p-aminobenzoic acid was carried out by a colorimetric assay (24), and activity with the hydrazine isoniazid was detected by the method of Olson et al. (19). Bacterial lysates and supernatants were diluted up to 50-fold with 20 mM Tris-HCl (pH 7.5) and 2 mM dithiothreitol before being used. Controls were carried out with identically diluted samples of E. coli cell lysate fractions that had been transformed with pET28b alone and demonstrated no activity under the conditions used. Likewise, insoluble pellets from E. coli cells expressing the M. tuberculosis nat gene or the M. smegmatis nat gene had no NAT enzymic activity. It was concluded that the NAT protein in these pellets was in inclusion bodies. Recombinant NAT from M. smegmatis in the supernatant fraction of E. coli is active in acetylating a series of substrates, including isoniazid, anisidine, and 4-aminoveratrole, which are also substrates of the S. typhimurium enzyme. The arylamine p-aminobenzoic acid is poorly acetylated by NAT from both M. smegmatis and S. typhimurium (24). Isoniazid is a better substrate (Km, 25 µM; Vmax/Km 2,520 × 10-6 liter · min-1 · mg of protein-1) than are the arylamines anisidine (Km, 300 µM; Vmax/Km, 16 × 10-6 liter · min-1 · mg of protein-1) and 4-aminoveratrole (Km, 650 µM; Vmax/Km, 25 × 10-6 liter · min-1 · mg of protein-1) for the NAT enzyme from M. smegmatis. These results suggest the enzyme has a substrate specificity similar to that of the S. typhimurium enzyme (24, 32).

Expression of mycobacterial nat genes in M. smegmatis. M. smegmatis and M. tuberculosis nat genes were also expressed by using the mycobacterial expression vector pACE-1. Competent M. smegmatis cells (Mc2155 [26]) were electroporated with 1 µg of plasmid DNA, either alone or containing the nat insert, at 700 Omega , 2.5 kV, and 25 µF (26). M. smegmatis cells were grown on the selective medium 7H9 supplemented with albumin-dextrose-catalase (Difco) or 7H11 agar supplemented with oleic acid-albumin-dextrose-catalase (Difco) containing hygromycin (50 µg/ml). Minimal medium was used for gene expression using the pACE-1 constructs (21). These constructs yield recombinant protein when acetamide (2 mg/ml) is supplied as the sole carbon source in the growth medium. M. smegmatis cell pellets were sonicated on ice 10 times, each for 1 min, with 30-s intervals between sonications. The resulting cell lysates were centrifuged at 100,000 × g for 60 min at 4°C. Supernatants were kept, and the pellets were resuspended to the original volume in resuspension buffer. With this expression vector, recombinant mycobacterial NAT protein was detected predominantly in the supernatant fraction (Fig. 3A). Cells expressing the M. smegmatis nat (Fig. 3A, lane 4) routinely had more recombinant protein than the cells expressing the M. tuberculosis nat gene (Fig. 3A, lanes 2 and 3). The sizes of the induced protein bands were around 30 kDa, which corresponds to the expected sizes for NAT proteins without a hexahistidine tag. The antiserum raised against the pure S. typhimurium NAT identified a band in the supernatants of M. smegmatis induced to express the M. smegmatis nat gene (Fig. 3B and C, lane 4) and, with longer exposure of the autoradiograph, the presence of M. tuberculosis NAT (Fig. 3C, lanes 2 and 3). There was also an indication of endogenous NAT (Fig. 3C, lane 1). The sizes of the endogenous and induced proteins (which have no hexahistidine tags) illustrated in Fig. 3 are indistinguishable, as expected. An antiserum raised against recombinant M. tuberculosis NAT, prepared by immunizing rabbits with insoluble recombinant protein excised from a polyacrylamide gel slice, was used at a dilution of 1:100,000 and is highly specific for M. tuberculosis NAT (Fig. 3D, lanes 2 and 3). It does not recognize M. smegmatis NAT under the conditions shown in Fig. 3D.


View larger version (47K):
[in this window]
[in a new window]
  		FIG. 3.   Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of recombinant NAT proteins in M. smegmatis. Gels were loaded with 15 µl of supernatants from lysates of M. smegmatis transformed with pACE-1 alone (lane 1), with M. tuberculosis nat (lanes 2 and 3), or with M. smegmatis nat (lane 4) (M, molecular mass markers [in kilodaltons]). (A) Staining with Coomassie blue. The arrow indicates the additional band in the supernatants transformed with a nat gene. (B to D) Western blots developed by using an enhanced chemiluminescence detection system as described previously (27), where exposure time for detection of the second antibody is either 1 min (B and D) or 20 min (C). In each panel, lane 1 has been loaded with 10 µg of total protein and lanes 2 to 4 have been loaded with 600 ng of total protein. An antiserum raised against recombinant M. tuberculosis NAT protein synthesized in E. coli is shown in panel D. The antiserum used in panels B and C is the antiserum against pure S. typhimurium NAT (24). Both antisera were used at a dilution of 1:100,000.

Overproduction of mycobacterial nat genes in M. smegmatis results in increased resistance to isoniazid. We have investigated whether the expression of the nat gene from M. tuberculosis alters the sensitivity of M. smegmatis to isoniazid in vivo. M. smegmatis transformants of pACE-1 either alone or containing the nat gene from M. tuberculosis were grown in minimal medium containing either acetamide to induce synthesis of protein or an equivalent carbon concentration of glucose which does not induce protein synthesis from the pACE-1 vector. Cultures were grown for up to 48 h in the presence of different amounts of isoniazid, and cell growth was determined at 600 nm with a plate reader (Titertek Multiskan). It was observed that when the expression of the nat gene was induced, there was an increase in the concentration of isoniazid in the growth medium that could be tolerated (Fig. 4). There was no change in the response to isoniazid in M. smegmatis cultures containing the nat gene construct when the growth conditions did not induce synthesis of recombinant NAT protein. In contrast, M. smegmatis cells, which contained only vector, were equally sensitive to isoniazid, irrespective of whether acetamide or glucose was the carbon source.


View larger version (12K):
[in this window]
[in a new window]
  		FIG. 4.   Effect of expression of M. tuberculosis nat on the growth of M. smegmatis in the presence of isoniazid (INH). Results for cultures of M. smegmatis either transformed with pACE-1 alone (open circles) or with pACE-1 containing M. tuberculosis nat (solid circles) grown in minimal medium containing acetamide and cultures of pACE-1 containing M. tuberculosis nat grown in minimal medium containing glucose (triangles) are shown.

Discussion. The existence of highly conserved arylamine N-acetyltransferase sequences in bacteria other than S. typhimurium suggests that the enzyme is conserved in evolution. The role of NAT in endogenous metabolism is unclear, although it has been suggested that in eukaryotes, NAT (in particular, the human NAT1 isoenzyme) plays a role in folate catabolism (16, 31). The very poor activity of the NAT from M. smegmatis or S. typhimurium with p-aminobenzoic acid can be rationalized on the basis that a supply of p-aminobenzoic acid is essential for folate synthesis in prokaryotes. The activity profile is more like that of the human isoenzyme NAT2 which is responsible for the inactivation, by acetylation, of isoniazid (18). NATs are present in several bacterial species, and a sequence similar to NAT has been identified in the completed genome sequence of E. coli (1). It has been demonstrated in the present study that the activity in E. coli with all substrates tested is less than 1% of the activity of the other recombinant NATs overproduced in E. coli. In addition to the overall homology, alignment of NAT sequences (Fig. 1) necessitates the introduction, in the bacterial sequences, of a gap of around 20 amino acids on the C-terminal region flanking the N- and C-terminal regions of the molecule (12). It has been suggested that the N-terminal region is predominantly alpha helix, while the C-terminal portion is predominantly beta sheet. The gap corresponds to the region linking these two secondary structure domains of the molecule. The bacterial NAT enzymes appear to be particularly stable to proteolysis, in contrast to the mammalian NAT enzymes (25), which may be due to the lack of a randomly structured loop in the bacterial NATS.

The expression of NAT in mycobacteria has important implications. Mycobacteria are exquisitely sensitive to isoniazid (14), although there are differences among the mycobacteria in their levels of sensitivity to the drug. M. tuberculosis will not grow in 0.2 µg of isoniazid per ml (21), and M. smegmatis will not grow in 5 µg of isoniazid per ml (7). When we induced the synthesis of more NAT in M. smegmatis, growth of the mycobacteria was not arrested until the concentration of isoniazid was 15 µg/ml. Isoniazid is inactivated in humans through acetylation (8, 9). The results presented here demonstrate that NAT is expressed endogenously in M. smegmatis and that the NAT proteins from mycobacteria can acetylate isoniazid and thus appear able to inactivate isoniazid in vivo. There is a body of evidence to demonstrate that the antimycobacterial activity of isoniazid in mycobacteria relies on the drug first becoming activated (11, 17, 23). It is already known that the acetylation of isoniazid inactivates the drug. The results presented here support the concept that the acetylation of isoniazid in mycobacteria acts in competition with the activation through oxidation. It is therefore important to investigate nat expression in other mycobacteria, including particularly M. tuberculosis, in which development of isoniazid resistance cannot be accounted for completely by currently identified loci (29).


    ACKNOWLEDGMENTS

We are extremely grateful to the Wellcome Trust for financial support.

We thank S. Martin for the preparation of the gridded libraries and D. Young, K. Duncan, and J. Sinclair for very helpful discussions. We also thank James Sandy for excellent technical assistance.


    FOOTNOTES

* Corresponding author. Mailing address: Department of Pharmacology, University of Oxford, Mansfield Rd., Oxford OX1 3QT, United Kingdom. Phone: (44 1865) 271596. Fax: (44 1865) 271853. E-mail: esim{at}worf.molbiol.ox.ac.uk.


    REFERENCES
Top
Abstract
Text
References

1. Blattner, F., G. Plunkett, C. Bloch, N. Perna, V. Burland, M. Riley, J. Collado-Vides, J. Glasner, C. Rode, G. Mayhew, J. Gregor, N. Davis, H. Kirkpatrick, M. Goeden, D. Rose, B. Mau, and Y. Shao. 1997. The complete genome sequence of Escherichia coli K12. Science 277:1453-1474[Abstract/Free Full Text].
2. Blum, M., D. M. Grant, W. McBride, M. Heim, and U. A. Meyer. 1990. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol. 9:193-203[Medline].
3. Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, and B. Barrel. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544[Medline].
4. Cribb, A. E., H. Nakamura, D. M. Grant, M. A. Miller, and S. P. Spielberg. 1993. Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism. Biochem. Pharmacol. 45:1277-1282[Medline].
5. Deguchi, T. 1992. Physiology and molecular biology of arylamine N-acetyltransferases. Biomed. Res. 13:231-242.
6. Delomenie, C., G. H. Goodfellow, R. Krishnamoorthy, D. M. Grant, and J. M. Dupret. 1997. Study of the role of the highly conserved residues Arg(9) and Arg(64) in the catalytic function of human N-acetyltransferases NAT1 and NAT2 by site-directed mutagenesis. Biochem. J. 323:207-215.
7. Dhandayuthapani, S., Y. Zhang, M. H. Mudd, and V. Deretic. 1996. Oxidadtive stress response and its role in sensitivity to isoniazid in mycobacteria: characterization and inducibility of ahpC by peroxides in Mycobacterium smegmatis and lack of expression in M. aurum and M. tuberculosis. J. Bacteriol. 178:3641-3649[Abstract/Free Full Text].
8. Ellard, G. A., and P. T. Gammon. 1976. Pharmacokenetics of isoniazid metabolism in man. J. Pharmacokinet. Biopharm. 4:83-113[Medline].
9. Evans, D. A. P., K. A. Manley, and V. A. McKuisick. 1960. Genetic control of isoniazid acetylation in man. Br. Med. J. 2:485-491.
10. Hein, D. W., M. A. Doll, K. Gray, T. D. Rustan, and R. J. Ferguson. 1993. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus. Cancer Res. 53:509-514[Abstract/Free Full Text].
11. Heym, B., Y. Zhang, S. Poulet, D. Young, and S. T. Cole. 1993. Characterization of the katG gene encoding catalase-peroxidase required for the isoniazid susceptibility of Mycobacterium tuberculosis. J. Bacteriol. 175:4255-4259[Abstract/Free Full Text].
12. Hubbard, T., A. Tramontano, and I. W. Team. 1996. Update on protein structure prediction: results of the 1995 IRBM Workshop. Protein Folding Design 1:R55-R63.
13. Jehne, J. W. 1965. Partial purification and properties of the isoniazid transacetylase in human liver: its relationship to the acetylation of p-aminosalicylic acid. J. Clin. Investig. 44:1992-2002.
14. Kruger-Thiemer, E. 1958. Isonicotinic acid hypothesis of the anti-tuberculosis action of isoniazid. Am. Rev. Tuberc. 78:364-367.
15. Lévy-Frébault, V. V., and F. Portaels. 1992. Proposed minimum standards for the genus Mycobacterium and for description of new slowly growing Mycobacterium species. Int. J. Syst. Bacteriol. 42:315-323[Abstract/Free Full Text].
16. Minchin, R. F. 1995. Acetylation of para-aminobenzoylglutamate, a folate catabolite, by recombinant human NAT and U937 cells. Biochem. J. 307:1-3.
17. Musser, M., V. Kapur, D. Williams, B. Kreiswirth, D. van Soolingen, and J. Van Embden. 1996. Characterisation of the catalase-peroxidase gene (katG) and inhA locus in isoniazid resistant and susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J. Infect. Dis. 173:196-202[Medline].
18. Ohsako, S., and T. Deguchi. 1990. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases of human liver. J. Biol. Chem. 265:4630-4634[Abstract/Free Full Text].
19. Olson, W., P. Dayton, Z. Israili, and A. Pruitt. 1977. Spectrophotofluorimetric assay for isoniazid and acetylisoniazid in plasma adapted to paediatric studies. Clin. Chem. 23/24:745-748.
20. Palamanda, J., D. Hickman, A. Ward, E. Sim, M. Romkes-Sparks, and J. Unadkat. 1995. Dapsone acetylation by human liver N-acetyltransferase and interaction with anti-opportunistic infection drugs. Drug Metab. Dispos. 23:473-477[Abstract].
21. Parish, T., E. Mahenthiralingam, P. Draper, E. O. Davis, and M. J. Colston. 1997. Regulation of the inducible amidase gene of Mycobacterium smegmatis. Microbiology 143:2267-2276[Abstract/Free Full Text].
22. Risch, A., V. Smelt, D. Lane, L. Stanely, W. van der Slot, A. Ward, and E. Sim. 1996. Arylamine N-acetyltransferase in erythrocytes of cystic fibrosis patients. Pharmacol. Toxicol. 78:235-240[Medline].
23. Rozwarski, D. A., G. A. Grant, D. H. R. Barton, W. R. Jacobs, and J. C. Sacchettini. 1998. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279:98-102[Abstract/Free Full Text].
24. Sinclair, J., R. Delgoda, M. Noble, S. Jarmin, N. Goh, and E. Sim. 1998. Purification, characterisation and crystallisation of an N-hydroxyarylamine O-acetyltransferase from Salmonella typhimurium. Prot. Expr. Purif. 12:371-380[Medline].
25. Sinclair, J., and E. Sim. 1997. A fragment consisting of the first 204 amino-terminal amino acids of human arylamine N-acetyl transferase one (NAT1) and the first transacetylation step of catalysis. Biochem. Pharmacol. 53:11-16[Medline].
26. Snapper, S. B., R. E. Melton, S. Mustafa, T. Kieser, and W. R. Jacobs. 1990. Isolation and characterisation of efficient plasmid transformation mutants of Mycobacterium smegmatis. Mol. Microbiol. 4:1911-1919[Medline].
27. Stanley, L., I. Mills, and E. Sim. 1997. Localisation of polymorphic N-acetyltransferase (NAT2) in tissues of inbred mice. Pharmacogenetics 7:121-130[Medline].
28. Vatsis, K. P., W. W. Weber, D. A. Bell, J. M. Dupret, D. A. Evans, D. M. Grant, D. W. Hein, H. J. Lin, U. A. Meyer, M. V. Relling, et al. 1995. Nomenclature for N-acetyltransferases. Pharmacogenetics 5:1-17[Medline].
29. Victor, T. C., R. Warren, J. L. Butt, A. M. Jordaan, J. V. Felix, A. Venter, F. A. Sirgel, H. S. Schaaf, P. R. Donald, M. Richardson, M. H. Cynamon, and P. D. VanHelden. 1997. Genome and MIC stability in Mycobacterium tuberculosis and indications for continuation of use of isoniazid in multidrug-resistant tuberculosis. J. Med. Microbiol. 46:847-857[Abstract/Free Full Text].
30. Ward, A., D. Hickman, J. W. Gordon, and E. Sim. 1992. Arylamine N-acetyltransferase in human red blood cells. Biochem. Pharmacol. 44:1099-1104[Medline].
31. Ward, A., M. Summers, and E. Sim. 1995. Purification of recombinant human NAT1 expressed in E. coli. Biochem. Pharm. 49:1759-1767[Medline].
32. Watanabe, M., T. Sofuni, and T. Nohmi. 1992. Involvement of Cys69 residue in the catalytic mechanism of N-hydroxyarylamine O-acetyltransferase of Salmonella typhimurium. Sequence similarity at the amino acid level suggests a common catalytic mechanism of acetyltransferase for S. typhimurium and higher organisms. J. Biol. Chem. 267:8429-8436[Abstract/Free Full Text].
33. Weber, W. W., and D. W. Hein. 1985. Arylamine N-acetyltransferases. Pharmacol. Rev. 37:25-79[Medline].
34. Weber, W. W., and K. P. Vatsis. 1993. Individual variability in p-aminobenzoic acid acetylation by human N-acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics 3:209-212[Medline].

Journal of Bacteriology, February 1999, p. 1343-1347, Vol. 181, No. 4
0021-9193/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Srivastava, V., Rouanet, C., Srivastava, R., Ramalingam, B., Locht, C., Srivastava, B. S. (2007). Macrophage-specific Mycobacterium tuberculosis genes: identification by green fluorescent protein and kanamycin resistance selection. Microbiology 153: 659-666 [Abstract] [Full Text]  
  • Suzuki, H., Ohnishi, Y., Horinouchi, S. (2007). Arylamine N-Acetyltransferase Responsible for Acetylation of 2-Aminophenols in Streptomyces griseus. J. Bacteriol. 189: 2155-2159 [Abstract] [Full Text]  
  • Adjei, M. D., Heinze, T. M., Deck, J., Freeman, J. P., Williams, A. J., Sutherland, J. B. (2006). Transformation of the Antibacterial Agent Norfloxacin by Environmental Mycobacteria. Appl. Environ. Microbiol. 72: 5790-5793 [Abstract] [Full Text]  
  • Sholto-Douglas-Vernon, C., Sandy, J., Victor, T. C, Sim, E., Helden, P. D. (2005). Mutational and expression analysis of tbnat and its response to isoniazid. J Med Microbiol 54: 1189-1197 [Abstract] [Full Text]  
  • Bhakta, S., Besra, G. S., Upton, A. M., Parish, T., Sholto-Douglas-Vernon, C., Gibson, K. J.C., Knutton, S., Gordon, S., daSilva, R. P., Anderton, M. C., Sim, E. (2004). Arylamine N-Acetyltransferase Is Required for Synthesis of Mycolic Acids and Complex Lipids in Mycobacterium bovis BCG and Represents a Novel Drug Target. JEM 199: 1191-1199 [Abstract] [Full Text]  
  • Hearn, M. J., Cynamon, M. H. (2004). Design and synthesis of antituberculars: preparation and evaluation against Mycobacterium tuberculosis of an isoniazid Schiff base. J Antimicrob Chemother 53: 185-191 [Abstract] [Full Text]  
  • Ramaswamy, S. V., Reich, R., Dou, S.-J., Jasperse, L., Pan, X., Wanger, A., Quitugua, T., Graviss, E. A. (2003). Single Nucleotide Polymorphisms in Genes Associated with Isoniazid Resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47: 1241-1250 [Abstract] [Full Text]  
  • Viveiros, M., Portugal, I., Bettencourt, R., Victor, T. C., Jordaan, A. M., Leandro, C., Ordway, D., Amaral, L. (2002). Isoniazid-Induced Transient High-Level Resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46: 2804-2810 [Abstract] [Full Text]  
  • Mushtaq, A., Payton, M., Sim, E. (2002). The COOH Terminus of Arylamine N-Acetyltransferase from Salmonella typhimurium Controls Enzymic Activity. J. Biol. Chem. 277: 12175-12181 [Abstract] [Full Text]  
  • Diaz, E., Ferrandez, A., Prieto, M. A., Garcia, J. L. (2001). Biodegradation of Aromatic Compounds by Escherichia coli. Microbiol. Mol. Biol. Rev. 65: 523-569 [Abstract] [Full Text]  
  • Payton, M., Gifford, C., Schartau, P., Hagemeier, C., Mushtaq, A., Lucas, S., Pinter, K., Sim, E. (2001). Evidence towards the role of arylamine N-acetyltransferase in Mycobacterium smegmatis and development of a specific antiserum against the homologous enzyme of Mycobacterium tuberculosis. Microbiology 147: 3295-3302 [Abstract] [Full Text]  
  • Deloménie, C., Fouix, S., Longuemaux, S., Brahimi, N., Bizet, C., Picard, B., Denamur, E., Dupret, J.-M. (2001). Identification and Functional Characterization of Arylamine N-Acetyltransferases in Eubacteria: Evidence for Highly Selective Acetylation of 5-Aminosalicylic Acid. J. Bacteriol. 183: 3417-3427 [Abstract] [Full Text]  
  • Payton, M., Mushtaq, A., Yu, T.-W., Wu, L.-J., Sinclair, J., Sim, E. (2001). Eubacterial arylamine N-acetyltransferases - identification and comparison of 18 members of the protein family with conserved active site cysteine, histidine and aspartate residues. Microbiology 147: 1137-1147 [Abstract] [Full Text]  
  • Sim, E., Payton, M., Noble, M., Minchin, R. (2000). An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes. Hum Mol Genet 9: 2435-2441 [Abstract] [Full Text]  
  • Vemulapalli, R., He, Y., Cravero, S., Sriranganathan, N., Boyle, S. M., Schurig, G. G. (2000). Overexpression of Protective Antigen as a Novel Approach To Enhance Vaccine Efficacy of Brucella abortus Strain RB51. Infect. Immun. 68: 3286-3289 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Payton, M.
Right arrow Articles by Sim, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Payton, M.
Right arrow Articles by Sim, E.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»